Free Republic

Washington, D.C. (May 9, 2022) – Today, Rep. James E. Clyburn, Chairman of the Select Subcommittee on the Coronavirus Crisis, issued the following statement after a staff briefing by Dr. Peter Marks, Director for the Center of Biologics Evaluation and Research at the Food and Drug Administration (FDA), on the status of coronavirus vaccine candidates for young children that took place on the afternoon of May 6. The briefing followed Chairman Clyburn’s April 25 letter to FDA Commissioner Dr. Robert M. Califf after reports emerged that the agency was considering delaying its review of the first coronavirus vaccine for children...

During December 14, 2020–April 10, 2021, data from the HEROES-RECOVER Cohorts,* a network of prospective cohorts among frontline workers, showed that the Pfizer-BioNTech and Moderna mRNA COVID-19 vaccines were approximately 90% effective in preventing symptomatic and asymptomatic infection with SARS-CoV-2, the virus that causes COVID-19, in real-world conditions (1,2). This report updates vaccine effectiveness (VE) estimates including all COVID-19 vaccines available through August 14, 2021, and examines whether VE differs for adults with increasing time since completion of all recommended vaccine doses. VE before and during SARS-CoV-2 B.1.617.2 (Delta) variant predominance, which coincided with an increase in reported COVID-19 vaccine...